行情

CORV

CORV

Correvio Pharma Corp
NASDAQ

实时行情|Nasdaq Last Sale

0.3706
+0.0026
+0.71%
盘后: 0.3700 -0.0006 -0.16% 18:57 04/09 EDT
开盘
0.3720
昨收
0.3680
最高
0.3790
最低
0.3611
成交量
134.83万
成交额
--
52周最高
3.056
52周最低
0.2100
市值
2,453.04万
市盈率(TTM)
-0.4528
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CORV价格均价为1.085,最高价位1.750,最低价为0.4200。

EPS

CORV 新闻

更多
  • 美股战“疫”小记:美股在这个早春都经历了什么?
  • 新浪财经综合 · 18分钟前
  • 疫情之下这几家或可跑赢大盘 苹果、亚马逊名列其中
  • 新浪科技综合 · 1小时前
  • 海底捞又涨价,这可能是投资良机
  • 新浪网 · 2小时前
  • 国际大米期货价格近来持续上涨
  • 新浪财经综合 · 2小时前

所属板块

制药
+0.59%
制药与医学研究
+0.82%

热门股票

代码
价格
涨跌幅

CORV 简况

Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops, acquires and commercializes brands for the in-hospital, acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba, for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, as well as Esmocard and Esmocard Lyo, a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil.
展开

微牛提供Correvio Pharma Corp(NASDAQ-CORV)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CORV股票新闻,以帮助您做出投资决策。